Two-year abatacept retention rate in clinical practice in the French ACTION cohort
| Autor: | Pascal Hilliquin, Xavier Mariette, M. Chartier, Alain Cantagrel, Virginie Vannier-Moreau, Julia Heitzmann, Philippe Gaudin, Thierry Schaeverbeke |
|---|---|
| Přispěvatelé: | Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes (IMVA-HB), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Groupe de Recherche et d’Étude du Processus Inflammatoire (GREPI), Université Joseph Fourier - Grenoble 1 (UJF)-EFS, Hôpital Pierre-Paul Riquet [Toulouse], CHU Toulouse [Toulouse], Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS) |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male musculoskeletal diseases medicine.medical_specialty Internationality Time Factors [SDV]Life Sciences [q-bio] Severity of Illness Index Drug Administration Schedule Body Mass Index Medication Adherence Abatacept Arthritis Rheumatoid Cohort Studies 03 medical and health sciences 0302 clinical medicine Rheumatology Rheumatoid Factor Internal medicine Humans Rheumatoid factor Medicine Prospective Studies 030212 general & internal medicine Aged 2. Zero hunger 030203 arthritis & rheumatology Dose-Response Relationship Drug business.industry Middle Aged Retention rate medicine.disease Clinical Practice Treatment Outcome Action study Antirheumatic Agents Rheumatoid arthritis Cohort Patient Compliance Female France business Body mass index Follow-Up Studies medicine.drug |
| Zdroj: | Joint Bone Spine Joint Bone Spine, Elsevier Masson, 2019, 86, pp.753-759. ⟨10.1016/j.jbspin.2019.07.006⟩ |
| ISSN: | 1297-319X |
| DOI: | 10.1016/j.jbspin.2019.07.006⟩ |
| Popis: | Abatacept retention rates were evaluated in the French cohort in the prospective ACTION study (2010-2013), which included patients with moderate-to-severe rheumatoid arthritis managed in everyday clinical practice and started on intravenous abatacept therapy.Two-year abatacept retention rates were evaluated in 455 patients classified according to treatment line, body mass index (BMI), and status for rheumatoid factor (RF) and anti-citrullinated peptide antibody (ACPA).After 2 years, the overall abatacept retention rate was 44%. The retention rate was non-significantly higher in the patients with vs. without a history of unresponsiveness to at least one biologic (48.1% vs. 41.8%, respectively). No significant retention rate differences were found across BMI categories (444 patients;25, 45.5%; ≥25 to30, 48.9%; and ≥30, 36.6%). Neither were any significant differences demonstrated according to RF and ACPA status (RF+ and ACPA+, 45.7%; RF+ or ACPA+, 43.8%; and FR- and ACPA-, 39.1%).The 44% 2-year retention rate in the French ACTION cohort supports the usefulness of abatacept therapy. In this study, retention was not associated with treatment line, BMI, or antibody status. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect